APGE Q2 2024 Earnings — Apogee Therapeutics, Inc. Revenue & Financial Results | Market Cap Arena

APGEApogee Therapeutics, Inc.

$4B

Q2 2024 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$0

Gross Profit

$0

Operating Income

-$44M

Net Income

-$34M

EPS (Diluted)

$-0.60

QoQ Revenue Growth

NaN%

Cash Flow

Operating Cash Flow

-$29M

Free Cash Flow

-$29M

Stock-Based Comp.

$6M

Balance Sheet

Total Assets

$801M

Total Liabilities

$27M

Stockholders' Equity

$774M

Cash & Equivalents

$307M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$0	$0	—
Gross Profit	$0	$0	—
Operating Income	-$44M	-$19M	-133.6%
Net Income	-$34M	-$19M	-79.1%